Celgene, Cyclacel cancer news

Cyclacel will sell Celgene patents covering the use of romidepsin injection in T cell lymphomas for $5.5 million. In conjunction, a judge in the U.S. District Court for the District of Delaware granted the companies' order for dismissal of a 2010 complaint in which Celgene sought declaratory judgment that the Cyclacel patents were invalid and not infringed by Celgene's products. The patents, collectively known as the Skov patents, are U.S. Patent Nos. 6,403,555; 6,548,479; 6,828,302; and 7,041,639. ...